Annexon (ANNX) Competitors $4.88 -0.18 (-3.56%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ANNX vs. CNTA, RXRX, APGE, IBRX, WVE, MIRM, AKRO, TARS, AMPH, and IRONShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Centessa Pharmaceuticals (CNTA), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), ImmunityBio (IBRX), Wave Life Sciences (WVE), Mirum Pharmaceuticals (MIRM), Akero Therapeutics (AKRO), Tarsus Pharmaceuticals (TARS), Amphastar Pharmaceuticals (AMPH), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Centessa Pharmaceuticals Recursion Pharmaceuticals Apogee Therapeutics ImmunityBio Wave Life Sciences Mirum Pharmaceuticals Akero Therapeutics Tarsus Pharmaceuticals Amphastar Pharmaceuticals Disc Medicine Annexon (NASDAQ:ANNX) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Does the media prefer ANNX or CNTA? In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than Annexon. MarketBeat recorded 12 mentions for Centessa Pharmaceuticals and 10 mentions for Annexon. Annexon's average media sentiment score of 1.01 beat Centessa Pharmaceuticals' score of 0.91 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ANNX or CNTA? Annexon has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, Centessa Pharmaceuticals has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Which has higher earnings and valuation, ANNX or CNTA? Annexon has higher earnings, but lower revenue than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$134.24M-$1.05-4.65Centessa Pharmaceuticals$6.85M338.61-$151.09M-$1.53-11.50 Is ANNX or CNTA more profitable? Annexon's return on equity of -38.99% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -38.99% -33.90% Centessa Pharmaceuticals N/A -52.13%-38.01% Do analysts rate ANNX or CNTA? Annexon currently has a consensus target price of $15.80, suggesting a potential upside of 223.77%. Centessa Pharmaceuticals has a consensus target price of $25.83, suggesting a potential upside of 46.78%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ANNX or CNTA? Annexon received 25 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 77.14% of users gave Annexon an outperform vote while only 56.86% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAnnexonOutperform Votes5477.14% Underperform Votes1622.86% Centessa PharmaceuticalsOutperform Votes2956.86% Underperform Votes2243.14% Do insiders and institutionals hold more shares of ANNX or CNTA? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 12.7% of Annexon shares are owned by company insiders. Comparatively, 11.6% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryAnnexon beats Centessa Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$520.18M$6.87B$5.18B$9.32BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-4.6510.75128.0017.55Price / SalesN/A288.101,260.27139.72Price / CashN/A56.6541.1637.95Price / Book1.535.394.874.92Net Income-$134.24M$152.04M$119.61M$225.78M7 Day Performance0.21%-5.54%14.55%-1.48%1 Month Performance-20.26%0.33%17.42%5.36%1 Year Performance74.91%16.04%35.34%22.71% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon2.3953 of 5 stars$4.88-3.6%$15.80+223.8%+74.9%$520.18MN/A-4.6560Analyst ForecastNews CoverageCNTACentessa Pharmaceuticals3.331 of 5 stars$16.38-1.1%$25.83+57.7%+147.5%$2.16B$6.85M-10.8372Insider TradeNews CoverageRXRXRecursion Pharmaceuticals2.5354 of 5 stars$7.46+7.3%$9.25+24.0%-26.6%$2.14B$44.58M-4.85400High Trading VolumeAPGEApogee Therapeutics2.729 of 5 stars$47.07+5.8%$83.88+78.2%+110.6%$2.12BN/A-18.3991Insider TradeShort Interest ↑News CoverageIBRXImmunityBio2.2677 of 5 stars$3.01+4.9%$17.38+477.2%-34.2%$2.10B$7.33M-3.36590WVEWave Life Sciences4.9175 of 5 stars$13.56+0.9%$22.22+63.9%+227.7%$2.07B$113.31M-12.11240Positive NewsMIRMMirum Pharmaceuticals4.1617 of 5 stars$42.32-0.3%$57.73+36.4%+22.1%$2.03B$307.03M-21.01140News CoverageAKROAkero Therapeutics3.9591 of 5 stars$29.04+0.5%$46.83+61.3%+33.6%$2.03BN/A-7.7030Short Interest ↓TARSTarsus Pharmaceuticals0.5082 of 5 stars$51.58-1.8%$54.20+5.1%+179.6%$1.97B$17.45M-13.7850Positive NewsAMPHAmphastar Pharmaceuticals4.8676 of 5 stars$40.90-3.2%$60.33+47.5%-27.8%$1.97B$644.40M14.081,761Insider TradeIRONDisc Medicine3.2945 of 5 stars$65.31+0.6%$87.50+34.0%+10.7%$1.94BN/A-16.3078 Related Companies and Tools Related Companies CNTA Competitors RXRX Competitors APGE Competitors IBRX Competitors WVE Competitors MIRM Competitors AKRO Competitors TARS Competitors AMPH Competitors IRON Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANNX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
